miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR

Sun,Chuanzheng; Huang,Feizhou; Liu,Xunyang; Xiao,Xuefei; Yang,Mingshi; Hu,Gui; Liu,Huaizheng; Liao,Liangkan

doi:10.3892/ijmm.2015.2076

miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR

Authors:
- Chuanzheng Sun
- Feizhou Huang
- Xunyang Liu
- Xuefei Xiao
- Mingshi Yang
- Gui Hu
- Huaizheng Liu
- Liangkan Liao
View Affiliations

Affiliations: Department of Emergency Medicine, The Third XiangYa Hospital of Central South University, Changsha, Hunan 410013, P.R. China
Published online on: January 21, 2015 https://doi.org/10.3892/ijmm.2015.2076
Pages: 847-853

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non-alcoholic fatty liver disease (NAFLD) has emerged as a public health issue with a prevalence of 15-30% in Western populations and 6-25% in Asian populations. Certain studies have revealed the alteration of microRNA (miRNA or miR) profiles in NAFLD and it has been suggested that miR-21 is associated with NAFLD. In the present study, we measured the serum levels of miR-21 in patients with NAFLD and also performed in vitro experiments using a cellular model of NAFLD to further investigate the effects of miR-21 on triglyceride and cholesterol metabolism. Furthermore, a novel target through which miR-21 exerts its effects on NAFLD was identified. The results revealed that the serum levels of miR-21 were lower in patients with NAFLD compared with the healthy controls. In addition, 3-hydroxy-3-methylglutaryl-co-enzyme A reductase (HMGCR) expression was increased in the serum of patients with NAFLD both at the mRNA and protein level. To mimic the NAFLD condition in vitro, HepG2 cells were treated with palmitic acid (PA) and oleic acid (OA). Consistent with the results obtained in the in vivo experiments, the expression levels of miR-21 were decreased and those of HMGCR were increased in the in vitro model of NAFLD. Luciferase reporter assay revealed that HMGCR was a direct target of miR-21 and that miR-21 exerted an effect on both HMGCR transcript degradation and protein translation. Furthermore, the results from the in vitro experiments revealed that miR-21 decreased the levels of triglycerides (TG), free cholesterol (FC) and total cholesterol (TC) in the PA/OA-treated HepG2 cells and that this effect was attenuated by HMGCR overexpression. Taken together, to the best of our knowledge, the present study is the first to report that miR-21 regulates triglyceride and cholesterol metabolism in an in vitro model of NAFLD, and that this effect is achieved by the inhibition of HMGCR expression. We speculate that miR-21 may be a useful biomarker for the diagnosis and treatment of NAFLD.

View Figures

View References

1	Targher G, Bertolini L, Padovani R, et al: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 30:1212–1218. 2007. View Article : Google Scholar : PubMed/NCBI
2	Clark JM and Diehl AM: Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep. 2:210–215. 2002. View Article : Google Scholar
3	Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 42:44–52. 2005. View Article : Google Scholar : PubMed/NCBI
4	Browning JD, Szczepaniak LS, Dobbins R, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 40:1387–1395. 2004. View Article : Google Scholar : PubMed/NCBI
5	Vernon G, Baranova A and Younossi ZM: Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 34:274–285. 2011. View Article : Google Scholar : PubMed/NCBI
6	Fan JG: An introduction of strategies for the management of nonalcoholic fatty liver disease (NAFLD) recommended by Asia Pacific Working Party on NAFLD. Zhonghua Gan Zang Bing Za Zhi. 15:552–553. 2007.In Chinese. PubMed/NCBI
7	Ballestri S, Lonardo A, Bonapace S, Byrne CD, Loria P and Targher G: Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 20:1724–1745. 2014. View Article : Google Scholar : PubMed/NCBI
8	Oni ET, Agatston AS, Blaha MJ, et al: A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? Atherosclerosis. 230:258–267. 2013. View Article : Google Scholar : PubMed/NCBI
9	Nelson KM and Weiss GJ: MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther. 7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
10	Xu P, Guo M and Hay BA: MicroRNAs and the regulation of cell death. Trends Genet. 20:617–624. 2004. View Article : Google Scholar : PubMed/NCBI
11	Karp X and Ambros V: Encountering microRNAs in cell fate signaling. Science. 310:1288–1289. 2005. View Article : Google Scholar : PubMed/NCBI
12	Li S, Chen X, Zhang H, et al: Differential expression of microRNAs in mouse liver under aberrant energy metabolic status. J Lipid Res. 50:1756–1765. 2009. View Article : Google Scholar : PubMed/NCBI
13	Cheung O, Puri P, Eicken C, et al: Nonalcoholic steatohepatitis is associated with altered hepatic microRNA expression. Hepatology. 48:1810–1820. 2008. View Article : Google Scholar : PubMed/NCBI
14	Jin X, Ye YF, Chen SH, Yu CH, Liu J and Li YM: MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis. 41:289–297. 2009. View Article : Google Scholar
15	Pogribny IP, Starlard-Davenport A, Tryndyak VP, Han T, Ross SA, Rusyn I and Beland FA: Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice. Lab Invest. 90:1437–1346. 2010. View Article : Google Scholar : PubMed/NCBI
16	Cazanave SC, Mott JL, Elmi NA, et al: JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem. 284:26591–26602. 2009. View Article : Google Scholar : PubMed/NCBI
17	Ahn J, Lee H, Jung CH and Ha T: Lycopene inhibits hepatic steatosis via microRNA-21-induced downregulation of fatty acid-binding protein 7 in mice fed a high-fat diet. Mol Nutr Food Res. 56:1665–1674. 2012. View Article : Google Scholar : PubMed/NCBI
18	Nehra V, Angulo P, Buchman AL and Lindor KD: Nutritional and metabolic considerations in the etiology of nonalcoholic steatohepatitis. Dig Dis Sci. 46:2347–2352. 2001. View Article : Google Scholar : PubMed/NCBI
19	Richieri GV and Kleinfeld AM: Unbound free fatty acid levels in human serum. J Lipid Res. 36:229–240. 1995.PubMed/NCBI
20	Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al: Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 120:1183–1192. 2001. View Article : Google Scholar : PubMed/NCBI
21	Belfort R, Harrison SA, Brown K, et al: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 355:2297–2307. 2006. View Article : Google Scholar : PubMed/NCBI
22	Yao HR, Liu J, Plumeri D, et al: Lipotoxicity in HepG2 cells triggered by free fatty acids. Am J Transl Res. 3:284–291. 2011.PubMed/NCBI
23	Beg ZH, Stonik JA and Brewer HB Jr: Phosphorylation of hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and modulation of its enzymic activity by calcium-activated and phospholipid-dependent protein kinase. J Biol Chem. 260:1682–1687. 1985.PubMed/NCBI
24	Beg ZH, Stonik JA and Brewer HB Jr: Modulation of the enzymic activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase by multiple kinase systems involving reversible phosphorylation: a review. Metabolism. 36:900–917. 1987. View Article : Google Scholar : PubMed/NCBI
25	Caballero F, Fernández A, De Lacy AM, Fernández-Checa JC, Caballería J and García-Ruiz C: Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J Hepatol. 50:789–796. 2009. View Article : Google Scholar : PubMed/NCBI
26	Min HK, Kapoor A, Fuchs M, et al: Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 15:665–674. 2012. View Article : Google Scholar : PubMed/NCBI
27	DeBose-Boyd RA: Feedback regulation of cholesterol synthesis: sterolaccelerated ubiquitination and degradation of HMG CoA reductase. Cell Res. 18:609–621. 2008. View Article : Google Scholar : PubMed/NCBI
28	Trapani L, Segatto M, Simeoni V, et al: Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin. Biochimie. 93:1165–1171. 2011. View Article : Google Scholar : PubMed/NCBI
29	Maron DJ, Fazio S and Linton MF: Current perspectives on statins. Circulation. 101:207–213. 2000. View Article : Google Scholar : PubMed/NCBI